Objective: To evaluate the clinical efficacy of integrated traditional Chinese medicine (TCM) treatment for obesity based on real-world data. Methods: A retrospective analysis was conducted on the clinical data of patients diagnosed with obesity at the Obesity Department of Hubei Provincial TCM Hospital from January 2023 to December 2023. The data collected included general information (name, age, gender), comorbidities, body weight, and treatment methods during the therapy period. The effect of the TCM integrated intervention program (including traditional Chinese herbal decoction, acupuncture point thread embedding, and TCM fasting therapy) on weight improvement in obese patients was analyzed. Results: Among the comorbidities in 1 468 obese patients, fatty liver disease had the highest proportion (63.42%). After integrated TCM intervention for 1, 2, 3, and 6 months, the percentage reduction in body weight was 3.80%, 5.86%, 8.00%, and 10.00%, respectively. At the 3-month treatment point, 70.28% of patients experienced a body weight reduction of ≥5%, and 34.64% had a reduction of ≥10%. After 6 months of treatment, the weight reduction in patients with severe obesity was the most significant, reaching 13.99%. Furthermore, the weight loss percentage in female patients was better than that of male patients (18.25% vs 12.22%). Conclusion: In real-world clinical practice, the integrated TCM intervention program effectively reduces the body weight of obese patients, with better weight loss effects in female patients with severe obesity compared to males. This provides evidence for the clinical application and promotion of TCM in obesity treatment.
Key words
obesity /
traditional Chinese medicine /
real-world clinical research /
efficacy evaluation /
target population
{{custom_keyword}} /
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] Blüher M. Obesity: global epidemiology and pathogenesis[J]. Nat Rev Endocrinol,2019,15(5): 288-298.
[2] Bray GA, Kim KK, Wilding JPH, et al. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation[J]. Obes Rev,2017,18(7):715-723.
[3] Ghaben AL, Scherer PE. Adipogenesis and metabolic health[J]. Nat Rev Mol Cell Biol,2019,20(4):242-258.
[4] Viewpoint: Toward Precision Approaches for the Prevention and Treatment of Obesity - PMC[EB/OL]. [2025-02-08]. https://pmc.ncbi.nlm.nih.gov/articles/PMC5787370/.
[5] Chen YK, Liu TT, Teia FKF, Xie MZ. Exploring the underlying mechanisms of obesity and diabetes and the potential of Traditional Chinese Medicine: an overview of the literature[J]. Front Endocrinol (Lausanne).2023,14:1218880.
[6] Fan Q, Xu F, Liang B, et al. The anti-obesity effect of traditional chinese medicine on lipid metabolism[J]. Frontiers in Pharmaco-logy, 2021, 12: 696603.
[7] Ma L, Bai Y, Liu J, et al. The therapeutic effects of traditional chinese medicine on insulin resistance in obese mice by modulating intestinal functions[J]. Heliyon, 2024, 10(9): e30379.
[8] 国家卫生健康委员会肥胖症诊疗指南编写委员会.肥胖症诊疗指南(2024年版)[J].中国循环杂志,2025,40(1):6-30.
[9] 中国营养学会肥胖防控分会,中国营养学会临床营养分会,中华预防医学会行为健康分会,等.中国居民肥胖防治专家共识[J].中国预防医学杂志, 2022, 23(5):19.
[10] 肖明中,闫瑞承,黄晶晶,等.基于态靶辨治理论体系构建肥胖症中医药系统性干预策略的思考[J].中西医结合肝病杂志,2023,33(7):577-581,587.
[11] 中华中医药学会《中医体质量管理临床指南》专家组,广东省针灸学会肥胖专病联盟.肥胖症中医诊疗方案专家共识[J].北京中医药大学学报,2022,45(8):786-794.
[12] 中华中医药学会肝胆病分会.穴位埋线治疗非酒精性脂肪性肝病中医实践指南[J].临床肝胆病杂志,2022,38(9):1990-1993.
[13] 李辉,肖明中,李恒飞,等.中医禁食疗法专家共识(征求意见稿)2019年第1版[J].中西医结合肝病杂志,2019,29(6):577-580.
[14] 张杰,艾星,王朝云,等.对体重控制药物临床试验设计的考虑[J].中国临床药理学杂志,2021,37(16):2245-2248.
[15] Gadde KM, Martin CK, Berthoud HR, et al. Obesity: pathophysiology and management[J].J Am Coll Cardiol,2018,71(1):69-84.
[16] Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, et al. Semaglutide vs Tirzepatide for weight loss in adults with overweight or obesi-ty[J].JAMA Intern Med,2024,184(9):1056-1064.
[17] 刘珍秀,秦利,黄怡文,等.中药复方治疗肥胖症疗效的随机对照试验Meta分析[J].上海中医药杂志,2023,57(2):26-34.
[18] Dai L, Wang M, Zhang KP, et al. Modified acupuncture therapy, long-term acupoint stimulation versus sham control for weight control: a multicenter, randomized controlled trial[J]. Front Endocrinol (Lausanne). 2022,13:952373.
[19] Liu T, Ye Z, Feng J, et al. Efficacy and safety of modified fasting therapy for weight loss in 2054 hospitalized patients[J]. Obesity (Silver Spring). 2023,31(6):1514-1529.
[20] Varlamov O,Bethea CL,Roberts CT Jr.Sex-specific differences in lipid and glucose metabolism[J].Front Endocrinol(Lausanne).2015,5:241.
[21] Hunter SK. Sex differences in human fatigability: mechanisms and insight to physiological responses[J]. Acta Physiol (Oxf). 2014,210(4):768-789.
[22] Christou EA, Jakobi JM, Critchlow A, et al.The 1- to 2-Hz oscillations in muscle force are exacerbated by stress, especially in older adults[J]. J Appl Physiol (1985). 2004,97(1):225-235.
[23] Salmón-Gómez L, Catalán V, Frühbeck G, Gómez-Ambrosi J. Relevance of body composition in phenotyping the obesities[J]. Rev Endocr Metab Disord,2023,24(5):809-823.
{{custom_fnGroup.title_en}}
Footnotes
{{custom_fn.content}}
PDF(3740 KB)
